Ocugen licenses OCU400 gene therapy to Roots Pharmaceutical for MENA region
Deal covers Middle East and North Africa rights to the retinitis pigmentosa therapy, with up to $259 million in potential payments and a 22% royalty.
Ocugen, Inc. announced on October 14, 2026 that it had completed a licensing agreement with Roots Pharmaceutical Company WLL and its strategic partner Al-Dhow International Holding for exclusive rights to OCU400, Ocugen's modifier gene therapy for retinitis pigmentosa, in the Middle East and North Africa. The Exclusive License Agreement, signed October 13, 2026, grants Roots an exclusive, non-sublicensable, royalty-bearing license to develop, register, and commercialize OCU400 in certain MENA countries, along with rights to use an Ocugen-selected trademark for the product.1
Under the terms, Ocugen will receive an up-front license fee and potential regulatory and development milestone payments of up to $4 million in the aggregate, payments upon achievement of certain sales milestones of up to $255.0 million, and a royalty of 22% on net sales of the licensed product generated by Roots in the Territory.1 The companies also entered into a commercial supply agreement under which Ocugen will manufacture and supply the licensed product to Roots.1
Roots will have sole control over preparing, filing and maintaining regulatory submissions in the Territory and has agreed to use commercially reasonable efforts to develop, register and commercialize the product there.1 Ocugen will retain ownership of the global safety database for the product.1 The agreement will remain in force until the later of 20 years after the first commercial sale in the Territory, expiration of relevant patent rights, or expiration of market exclusivity, at which point it terminates automatically.1
Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical trial, with a topline data readout expected in the first quarter of 2027, to be followed by global regulatory submissions including a Biologics License Application in the U.S. and a Marketing Authorization Application in Europe.1
Separately, the filing noted that Ocugen's Board postponed a Special Meeting of Stockholders, previously adjourned to October 26, 2026, with respect to a proposal to increase authorized common shares by 250,000,000, rescheduling the meeting to December 22, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.